Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference

Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth
Conference

LAIYANG, China, Nov. 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo
Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the "Company" or "Jiangbo"),
a pharmaceutical company with its principal operations in China, today
announced that the Company's management will present at the upcoming Brean
Murray, Carret & Co. 2009 China Growth Conference.
Date: November 19, 2009
Time: 10:40 a.m. - 11:15 a.m. EST
Presenter: Ms. Elsa Sung, CFO
Location: The Millennium Broadway Hotel
New York, NY

The Brean Murray, Carret & Co. 2009 China Growth Conference is a
two-day conference (November 19-20, 2009) that consists of 25-minute
presentation slots followed by 10-minutes of open floor Q&A sessions with
institutional investors. Senior management of presenting companies, industry
experts, and institutional investors will receive a unique and comprehensive
view of China from a global perspective. Jiangbo's management will be
available for 1x1 meetings before and after the Company's presentation.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development,
production, marketing and sales of pharmaceutical products in China. The
Company's operations are located in Eastern China in an Economic Development
Zone in Laiyang City, Shandong Province. Jiangbo produces both western and
Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and
electuary (sticky syrup) form. For additional information, please visit the
Company's website ( http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements are not guarantees of future
performance and are subject to risks and uncertainties that could cause the
Company's actual results and financial position to differ materially from
those included within the forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from anticipated or predicted results, and reported results should
not be considered as an indication of future performance. The potential risks
and uncertainties include, among others, the Company's ability to obtain raw
materials needed in manufacturing, the continuing employment of key employees,
the failure risks inherent in testing any new drug, the possibility that
regulatory approvals may be delayed or become unavailable, patent or licensing
concerns that may include litigation, direct competition from other
manufacturers and product obsolescence. More information about the potential
factors that could affect the Company's business and financial results is
included in the Company's filings, available via the United States Securities
and Exchange Commission.
For more information, please contact:

Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-727-8435
Email: elsasung@jiangbo.com
Web: http://www.jiangbopharma.com

CCG Investor Relations, Inc.
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Web: http://www.ccgirasia.com

SOURCE Jiangbo Pharmaceuticals, Inc.

Ms. Elsa Sung, CFO of Jiangbo Pharmaceuticals, Inc., +1-954-727-8435, or
elsasung@jiangbo.com; or at CCG Investor Relations, Inc., Mr. Crocker Coulson,
President, +1-646-213-1915, or crocker.coulson@ccgir.com, for JGBO